tiprankstipranks
TipRanksStock Market NewsALT NewsJMP Securities Thinks Altimmune’s Stock is Going to Recover
Blurbs

JMP Securities Thinks Altimmune’s Stock is Going to Recover

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Altimmune (ALTResearch Report), with a price target of $22.00. The company’s shares closed last Thursday at $4.28, close to its 52-week low of $3.89.

According to TipRanks.com, Wolleben is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -28.9% and a 14.4% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $26.17, implying a 557.5% upside from current levels. In a report issued on April 28, B.Riley Financial also maintained a Buy rating on the stock with a $21.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $19.46 and a one-year low of $3.89. Currently, Altimmune has an average volume of 852.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

Read More on ALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More